Effective October 1, 2026, arXiv has instituted a new rate‑limit policy that restricts each submitter to no more than two submissions per calendar month and a maximum of three active submissions at any given time. The change responds to a sharp rise in monthly submissions, which grew from 9,869 in September 2016 to 20,569 in September 2024 and reached 40,363 submissions in September 2026 — nearly double the volume from just two years earlier. This surge produced almost 9,000 support tickets for arXiv staff and moderators in a single month.
The article states that monthly submissions grew from 9,869 in September 2016 to 20,569 in September 2024 and reached 40,363 in September 2026, prompting the new rate‑limit policy.
The policy aims to curb the growing volume of low‑value submissions that have accompanied the increase. While arXiv permits the use of AI tools when properly disclosed and when the work meets its scholarly standards, the blog notes that AI‑assisted authoring has led to thin papers of narrow scope, ‘salami’ slicing of single works into multiple submissions, and dense AI‑written papers that lack substantial contribution. These submissions consume a disproportionate share of volunteer moderators’ time, delaying the review of higher‑quality papers from authors who continue to submit rigorous research. By limiting submission frequency, arXiv seeks to distribute moderator effort more fairly and protect the repository from inappropriate content.
arXiv characterizes the update as a stopgap measure while it develops better moderation tools and determines what constitutes best practice for authors employing increasingly advanced AI tools. The FAQ accompanying the announcement clarifies that rejected submissions still count toward the monthly limit, that deletions before announcement remove the paper from the count, and that co‑authors’ submission limits are unaffected. However, the source does not specify how the policy will evolve or address edge cases such as revised versions of existing papers, leaving the long‑term effectiveness and potential unintended consequences uncertain.